AbCellera Biologics

formerly AbCellera Biologics Inc. Common SharesIPO

Technologies for faster and better antibody discovery

Public · Vancouver, Canada · Founded 2012 · $115.8M raised

Headquarters
Vancouver
Employees
501–1000
Founded
2012
Business Model
B2B
Total Funding
$115.8M
Last Round
$105.0M Series BMay 2020
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

AbCellera is a clinical-stage biotechnology company founded in 2012 in Vancouver, Canada, by scientists who pioneered microfluidics and single-cell analysis technologies for antibody discovery. Its integrated platform has supported over 100 therapeutic antibody discovery programs with biopharma partners, and since 2023 the company has shifted focus toward advancing its own pipeline of programs in oncology, endocrine/metabolic conditions, and inflammation & autoimmunity.

Summary

AbCellera Biologics is a Biotech company based in Vancouver, Canada, founded in 2012. It has raised $115.8M in total across 5 rounds, most recently a $105.0M Series B round in May 2020. Investors include DCVC (Data Collab), OrbiMed and Viking Global.

Tech & App Stack

9 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPODec 2020
$555.5M

Sign up to see all 7 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Neuralink

Neuralink develops investigational implantable brain-computer interfaces that help people with pa...

Fremont, United States201–500Biotech, Healthcare
Series ETotal funding$1.2BJun 2025
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Artificial Intelligence, Healthcare
Series ETotal funding$1.1BJun 2022
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AbCellera Biologics on Indexed.vc
<a href="https://indexed.vc/companies/abcellera-biologics"><img src="https://indexed.vc/api/badge/company/abcellera-biologics" alt="AbCellera Biologics on Indexed.vc" width="260" height="76" /></a>